Overview

• More than half of vaccinated pancreatic ductal adenocarcinoma models achieved complete tumor remission months after treatment
• The vaccine leverages lipid nanoparticles engineered with multiple antigens reflecting the most common PDAC mutations to stimulate potent T-cell responses
• Researchers plan to pair the nanoparticle vaccine with immune checkpoint inhibitors to bolster anti-tumor immunity in further preclinical work
• A $3.27 million grant from the National Cancer Institute will fund optimization of vaccine formulations and comprehensive safety testing
• Long-term immune memory observed in models suggests potential for both treatment and prevention in genetically susceptible individuals